medigraphic.com
Colegio de Medicina Interna de México.

2021, Number 3

<< Back Next >>

Med Int Mex 2021; 37 (3)

Multiple myeloma and COVID-19

López-Lievanos MÁ, Mendoza-Gómez JL, Albarrán-Moreno M

Language: Spanish
References: 18
Page: 448-453
PDF size: 640.98 Kb.


ABSTRACT

Background: The current COVID-19 pandemic modifies current immunosuppressive treatment guidelines against several nephrological diseases.
Clinical case: A 69-year-old female patient. Her current condition began with a nonspecific clinical picture of asthenia, adynamia, abdominal pain, nausea, and emesis. Upon admission to the service, serum sodium of 111 was found and correction of hydro-electrolytic imbalance was performed. Serum creatinine of 4.41 was found with an estimated glomerular filtration rate of 9.6 mL/min/1.73m2, in addition to hemoglobin anemia of 6.3 mg/dL. A TNK catheter was inserted in the operating room. While in the peritoneal dialysis unit, patient regained kidney function with a filtration rate of 20 mL/min. Patient was then readmitted to the internal medicine floor, where anemia and persistent hypercalcemia stood out. After being evaluated by the Hematology service, final diagnosis was multiple myeloma. Shortly before starting treatment, patient started exhibiting fever, cough, and headache. Chest tomography provided data suggestive of COVID-19.
Conclusions: The clinical manifestations of multiple myeloma and chronic kidney disease are very varied, so the diagnostic approach is very important to avoid wrong diagnoses.


REFERENCES

  1. Gerecke C, Fuhrmann S, Strifler S, Schmidt-Hieber M, et al. The diagnosis and treatment of multiple mieloma. Dtsch Arztebl Int 2016; 113: 470-6. doi. 10.3238/arztebl. 2016.0470.

  2. Palumbo A, Anderson K. Multiple myeloma. N Eng J Med 2011; 364: 1046-1060.

  3. Alvarado-Ibarra M, Álvarez-Vera JL, Anaya-Cuéllar I, De la Peña-Celaya A, et al. Primer Consenso Nacional de Mieloma Múltiple por Hematólogos del ISSSTE. Rev Hematol Mex 2015; 16: 306-332.

  4. Bergstrom DJ, Kotb R, Louzada ML, Sutherland HJ, et al. Consensus Guidelines on the Diagnosis of Multiple Myeloma and Related Disorders: Recommendations of the Myeloma Canada Research Network Consensus Guideline Consortium. Clin Lymphoma Myeloma Leuk 2020; 20 (7): 352-367. doi. 10.1016/j.clml.2020.01.017.

  5. Yavorkovsky LL, Hope A. A tale of two immunodeficiencies: A case of multiple myeloma associated with profound immune defect mimicking common variable immunodeficiency syndrome. Perm J 2020; 24: 19.104. https://doi. org/10.7812/TPP/19.104.

  6. Fairfield H, Falank C, Avery L, Reagan MR, et al. Multiple myeloma in the marrow: pathogenesis and treatments. Ann NY Acad Sci 2016; 1364 (1): 32-51. doi. 10.1111/nyas.13038.

  7. Bird S, Boyd K. Multiple myeloma: an overview of management. Paliative Care & Social Practice 2019; 13: 1-13. doi. 10.1177/ 1178224219868235.

  8. Rajkumar V. Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol 2018; 93: 1091-1110. doi. 10.1002/ajh.25117.

  9. Jameson J, Fauci A, Kasper D, Hauser S, et al. Harrison Principios de Medicina Interna. 20ª ed. México: McGraw- Hill, 2018: 793-802.

  10. Leung N, Nasr S. Myeloma-related kidney disease. Advances in Chronic Kidney Disease 2014; 21 (1): 36-47. doi. https://doi.org/10.1053/j.ackd.2013.08.009.

  11. Santamaría-Carmona S, García-Palma MJ, Baena-Camús L, Rivas-del Valle PA. Insuficiencia renal como primera manifestación del mieloma múltiple. SEMERGEN 2006; 32 (6): 296-8. doi. 10.1016/S1138-3593(06)73274-9.

  12. Lichtman M, et al. Williams Manual de Hematología. 81ª ed. México: McGraw-Hill, 2014: 508-523.

  13. Lahoti A, Glass W. Multiple myeloma and the kidney. J Onco-Nephrol 2017; 1 (2): 95-102.

  14. Lakhwani S, Hernández M, Lorenzo-Barreto P, Cabrera D, et al. Early death in multiple myeloma. Analysis of patients in real-world practice. Blood 2018; 132 (1): 5595. https:// doi.org/10.1182/blood-2018-99-114129.

  15. Rajjumar V, Fonseca R, Jiménez M. Diagnosis and staging of multiple myeloma and related disorders. Multiple myeloma and other plasma cell neoplasms. 2018; 17-28. doi. 0.1007/978-3-319-25586-6_2.

  16. COVID-19 and multiple myeloma: Frequently asked questions [Internet]. Hematology 2020 [citado 25 julio 2020]. Disponible en: https://www.hematology.org/covid-19/ covid-19-and-multiple-myeloma.

  17. Li L, Wang L. Multiple myeloma: What do we do about immunodeficiency? J Cancer 2019; 10 (7): 1675-1684. doi. 10.7150/jca.29993.

  18. Hafeez A, Ahmad S, Siddqui S, Ahmad M, et al. A review of COVID-19 (coronavirus disease-19) diagnosis, treatments and prevention. EJMO 2020; 4 (2): 116-125. doi. 10.14744/ ejmo.2020.90853.




2020     |     www.medigraphic.com